Advanced in Inflammatory Breast Cancer

Dr. David B. Page

Oncology
4805 Northeast Glisan Street, Suite 11N-1, 
Portland, OR 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
17 Years of Experience
Advanced in Inflammatory Breast Cancer
4805 Northeast Glisan Street, Suite 11N-1, 
Portland, OR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Page is an Oncologist in Portland, Oregon. Dr. Page has been practicing medicine for over 17 years and is rated as an Advanced provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma. Dr. Page is currently accepting new patients.

His clinical research consists of co-authoring 39 peer reviewed articles and participating in 21 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2009
Specialties
Oncology
Licenses
Internal Medicine in NY
Hospital Affiliations
Providence Newberg Medical Center
Providence Milwaukie Hospital
Providence Willamette Falls Medical Center
Providence Portland Medical Center
Providence St Vincent Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Hawaii Medical Assurance Association
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Moda Health
  • EPO
  • PPO
Prominence Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

4805 Northeast Glisan Street, Suite 11N-1, Portland, OR 97213

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

A Single Arm Phase 2 Study of Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer.
A Single Arm Phase 2 Study of Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer.
Enrollment Status: Recruiting
Publish Date: September 15, 2025
Intervention Type: Drug, Procedure
Study Drug: Ipilimumab
Study Phase: Phase 2
An Open-label, Phase 1, Dose-escalation Study to Evaluate the Safety and Preliminary Antitumor Activity of TAK-676 With Pembrolizumab Following Radiation Therapy in the Treatment of Non-small-cell Lung Cancer, Triple-negative Breast Cancer, or Squamous-cell Carcinoma of the Head and Neck That Has Progressed on Checkpoint Inhibitors
An Open-label, Phase 1, Dose-escalation Study to Evaluate the Safety and Preliminary Antitumor Activity of TAK-676 With Pembrolizumab Following Radiation Therapy in the Treatment of Non-small-cell Lung Cancer, Triple-negative Breast Cancer, or Squamous-cell Carcinoma of the Head and Neck That Has Progressed on Checkpoint Inhibitors
Enrollment Status: Completed
Publish Date: September 04, 2025
Intervention Type: Drug, Radiation
Study Drugs: Pembrolizumab, TAK-676
Study Phase: Phase 1
Induction Immunotherapy to Promote Immunologic Priming and Enhanced Response to Neoadjuvant Pembrolizumab + Chemotherapy in Triple Negative Breast Cancer (TNBC)
Induction Immunotherapy to Promote Immunologic Priming and Enhanced Response to Neoadjuvant Pembrolizumab + Chemotherapy in Triple Negative Breast Cancer (TNBC)
Enrollment Status: Active_not_recruiting
Publish Date: July 14, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, IRX 2
Study Phase: Phase 2
Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI0562) Administered Prior to Surgical Resection in Patients With Head and Neck Squamous Cell Carcinoma or Melanoma
Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI0562) Administered Prior to Surgical Resection in Patients With Head and Neck Squamous Cell Carcinoma or Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drug: MEDI0562
Study Phase: Phase 1
Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)
Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2025
Intervention Type: Procedure, Drug, Radiation
Study Drug: Nivolumab
Study Phase: Phase 1/Phase 2
A Phase I/II Study of MK-3475 With Gemcitabine in Patients With Previously-Treated Advanced Non-small Cell Lung Cancer (NSCLC)
A Phase I/II Study of MK-3475 With Gemcitabine in Patients With Previously-Treated Advanced Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drugs: MK-3475, Gemcitabine
Study Phase: Phase 1/Phase 2
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab (neoHIP)
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab (neoHIP)
Enrollment Status: Active_not_recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, Trastuzumab, Pertuzumab, Pembrolizumab
Study Phase: Phase 2
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
Intratumoral Ipilimumab in Head and Neck Cancer
Intratumoral Ipilimumab in Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drug: Ipilimumab
Study Phase: Phase 1
A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Chemotherapy in Metastatic Triple Negative Breast Cancer Patients
A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Chemotherapy in Metastatic Triple Negative Breast Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Paclitaxel, Capecitabine
Study Phase: Phase 1/Phase 2
Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma
Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Drug, Procedure
Study Drugs: LY2157299, Capecitabine, Fluorouracil
Study Phase: Phase 2
A Phase II Study of Nivolumab Combined With Bicalutamide and Ipilimumab in Metastatic HER2-negative Breast Cancer
A Phase II Study of Nivolumab Combined With Bicalutamide and Ipilimumab in Metastatic HER2-negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab, Bicalutamide
Study Phase: Phase 2
Phase Ib Study of Neoadjuvant DPX-Survivac, Aromatase Inhibition, and With/Without Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
Phase Ib Study of Neoadjuvant DPX-Survivac, Aromatase Inhibition, and With/Without Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Drug, Radiation, Biological
Study Drugs: DPX-Survivac, Letrozole, Cyclophosphamide
Study Phase: Phase 1
Phase 1 Trial of Intravenous Administration of TAEK-VAC-HerBy Vaccine Alone and in Combination With HER2 Antibodies in Patients With Advanced Cancer.
Phase 1 Trial of Intravenous Administration of TAEK-VAC-HerBy Vaccine Alone and in Combination With HER2 Antibodies in Patients With Advanced Cancer.
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Biological
Study Drug: TAEK-VAC-HerBy
Study Phase: Phase 1
A Phase 1/2 Study of Tucatinib With Chemotherapy and Trastuzumab in Patients With Previously Treated, Advanced Her-2-Neu Overexpressing Breast Cancer.
A Phase 1/2 Study of Tucatinib With Chemotherapy and Trastuzumab in Patients With Previously Treated, Advanced Her-2-Neu Overexpressing Breast Cancer.
Enrollment Status: Withdrawn
Publish Date: June 22, 2023
Intervention Type: Drug
Study Drug: Tucatinib
Study Phase: Phase 1/Phase 2
Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma, Non-Small Cell Lung Cancer, and Head and Neck Squamous Cell Carcinoma.
Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma, Non-Small Cell Lung Cancer, and Head and Neck Squamous Cell Carcinoma.
Enrollment Status: Completed
Publish Date: June 05, 2023
Intervention Type: Drug
Study Drugs: Galactoarabino-Rhamnogalactouronate, Pembrolizumab
Study Phase: Phase 1
A Phase 2 Study to Assess the Safety and Efficacy of Scalp Cooling Using PenguinTM Cold Caps for the Prevention or Reduction of Chemotherapy-induced Alopecia in Stage I-III Breast Cancer
A Phase 2 Study to Assess the Safety and Efficacy of Scalp Cooling Using PenguinTM Cold Caps for the Prevention or Reduction of Chemotherapy-induced Alopecia in Stage I-III Breast Cancer
Enrollment Status: Unknown
Publish Date: September 16, 2020
Intervention Type: Device
Study Phase: Not Applicable
Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy.
Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy.
Enrollment Status: Completed
Publish Date: March 21, 2019
Intervention Type: Biological
Study Phase: Phase 1
Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
Enrollment Status: Completed
Publish Date: March 21, 2019
Intervention Type: Biological
Study Phase: Phase 1
Phase I Study of Safety and Immunogenicity of ADU-623, a Live-attenuated Listeria Monocytogenes Strain (ΔactA/ΔinlB) Expressing the EGFRvIII-NY-ESO-1 Vaccine, in Patients With Treated and Recurrent WHO Grade III/IV Astrocytomas
Phase I Study of Safety and Immunogenicity of ADU-623, a Live-attenuated Listeria Monocytogenes Strain (ΔactA/ΔinlB) Expressing the EGFRvIII-NY-ESO-1 Vaccine, in Patients With Treated and Recurrent WHO Grade III/IV Astrocytomas
Enrollment Status: Completed
Publish Date: August 17, 2018
Intervention Type: Biological, Drug
Study Phase: Phase 1
Phase I Study of Alpha-tocopheryloxyacetic Acid (α-TEA) in Patients With Advanced Cancer
Phase I Study of Alpha-tocopheryloxyacetic Acid (α-TEA) in Patients With Advanced Cancer
Enrollment Status: Completed
Publish Date: August 17, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 20 Less Clinical Trials

39 Total Publications

Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer.
Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer.
Journal: The Journal of pathology
Published: June 15, 2023
Similar Doctors
Distinguished in Inflammatory Breast Cancer
Dr. Jay C. Andersen
Oncology
Distinguished in Inflammatory Breast Cancer
Dr. Jay C. Andersen
Oncology
12123 Southwest 69th Avenue, 
Tigard, OR 
 (10.0 miles away)
971-708-7600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jay Andersen is an Oncologist in Tigard, Oregon. Dr. Andersen is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, HER-2 Positive Breast Cancer, and Inflammatory Breast Cancer. Dr. Andersen is currently accepting new patients.

Distinguished in Inflammatory Breast Cancer
Dr. Gary R. Cecchi
Hematology Oncology | Hematology | Oncology
Distinguished in Inflammatory Breast Cancer
Dr. Gary R. Cecchi
Hematology Oncology | Hematology | Oncology
505 Ne 87th Ave Ste 320, 
Vancouver, WA 
 (6.9 miles away)
360-514-2550
Languages Spoken:
English, Spanish
See accepted insurances

Gary Cecchi is a Hematologist Oncology specialist and a Hematologist in Vancouver, Washington. Dr. Cecchi is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Inflammatory Breast Cancer, Breast Cancer, Paget Disease of the Breast, and Thrombotic Thrombocytopenic Purpura.

Advanced in Inflammatory Breast Cancer
Dr. Alison K. Conlin
Oncology
Advanced in Inflammatory Breast Cancer
Dr. Alison K. Conlin
Oncology
4805 Northeast Glisan Street, Suite 11N-1, 
Portland, OR 
 (0.1 miles away)
503-215-5696
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alison Conlin is an Oncologist in Portland, Oregon. Dr. Conlin is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Endoscopy, and Colonoscopy. Dr. Conlin is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Page's expertise for a condition
ConditionClose
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile